Last reviewed 2026-04-19 · How we verify

hypercholesterolemia

Approved treatments

• Inosital
  Inosital works by influencing the metabolism of lipids in the body.
• Niaspan · Medpointe Pharm Hlc
• Ezetrol · NVP Healthcare
• Lerochol · Lib Therapeutics, Inc.
  Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels.
• Niaspan · Cedars-Sinai Medical Center
• Lescol · Novartis
  Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol.
• Praluent · Sanofi
  Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels.
• Colestid · Pfizer
• Zetia · Merck & Co.
  Zetia works by blocking the absorption of cholesterol in the small intestine.
• Lorelco
• Livalo · Kowa Research Institute, Inc.
• Lipitor · Pfizer Inc.
  Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.
• Zocor · Merck & Co.
• Praluent · Regeneron Pharmaceuticals
• Questran Light · Bristol Myers
• Myoinositol · University of Colorado, Denver
• Nicotinic Acid · MEDPOINTE PHARM HLC
• Tricor (Micronized) · Salix
  Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion.
• Welchol · Cosette
  Welchol works by binding to bile acids in the gut, reducing their reabsorption and increasing their excretion, which in turn lowers cholesterol levels and improves blood sugar control.
• Crestor · AstraZeneca
  Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor.
• Lipitor · Pfizer
  Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis.
• Befizal
• Repatha · Repatha
  Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.
• Trilipix · AbbVie
• Livalo · Kowa Co
• Baycol · Bayer
• Mevacor · Merck & Co.
  Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
• Welchol · Daiichi Sankyo

Clinical guidelines

• FDA label — adj
  As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
• FDA label — adj
  As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
• FDA label — adj
  As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
• FDA label — adj
  As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
• FDA label — adj
  As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• hypercholesterolemia patent landscape — cliff calendar, originator estates, attackable patents
• hypercholesterolemia treatment landscape brief
• hypercholesterolemia treatment updates RSS

Frequently asked questions about hypercholesterolemia

Related

• Treatment landscape: hypercholesterolemia patent cliff · hypercholesterolemia CI report
• Treatment: Inosital
• Treatment: Niaspan · Medpointe Pharm Hlc
• Treatment: Ezetrol · NVP Healthcare
• Treatment: Lerochol · Lib Therapeutics, Inc.
• Treatment: Niaspan · Cedars-Sinai Medical Center
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing